Compare BridgeBio Pharma Inc (BBIO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Redwire Corporation — how do they compare? BridgeBio Pharma Inc trades at $82.37 (market cap $16.46B), while Redwire Corporation trades at $9.37 (market cap $2.33B). The key difference: BridgeBio Pharma Inc is far larger — about 7.1× Redwire Corporation's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| BBIO | RDW | |
|---|---|---|
Market Cap | $16.46B | $2.33B |
Sector | Health | Technology |
52-Week High | $90.17 | $25.90 |
52-Week Low | $44.81 | $5.06 |
Enterprise Value | $18.02B | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
RDW trades at $9.59, down 5.8% with bearish technical signals despite 80% analyst buy ratings. The company shows significant revenue growth but deep losses, with net income margin at -80.9% and negative cash flow from operations. Recent news highlights dilution concerns from a $500M stock offering and competitive pressure from SpaceX's market dominance.
The stock presents high-risk potential with analyst consensus target of $19.00 representing 98% upside, but requires improved profitability and reduced cash burn. Key risks include persistent losses, dilution from financing activities, and intense space sector competition that could limit near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
